Skip to main content

The latest developments in oncology research

Drugmakers and, largely, the FDA argue that the medicines now being reviewed are different than the chemotherapies and blunter interventions of the past. This is having consequences for how clinical trials are being run, and for how much money drugmakers are investing in cancer R&D.

included in this trendline
  • Bristol Myers bets $4B on Turning Point and its targeted cancer drugs
  • Roche keeps the faith in new cancer immunotherapy despite trial setbacks
  • ‘Dramatic’ study results for AstraZeneca, Daiichi drug suggest new way to treat aggressive breast cancer
Our Trendlines go deep on the biggest trends. These special reports, produced by our team of award-winning journalists, help business leaders understand how their industries are changing.
Davide Savenije Editor-in-Chief at Industry Dive.